نتائج البحث - "romosozumab"

1

دورية أكاديمية

Une nouveauté dans la prise en charge de l’ostéoporose post-ménopausique à très haut risque fracturaire : le romosozumab (Evenity®), un anticorps monoclonal anti-sclérostine.
A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody.

المؤلفون: Bolland, Meilyn, Malaise, Olivier, Ribbens, Clio

المصدر: Revue Médicale de Liège, 78 (4), 239 - 244 (2023-04)

العلاقة: urn:issn:0370-629X; urn:issn:2566-1566

الوصول الحر: https://orbi.uliege.be/handle/2268/312146Test

View record in ORBi

2

دورية أكاديمية

Une nouveauté dans la prise en charge de l’ostéoporose post-ménopausique à très haut risque fracturaire : le romosozumab (Evenity®), un anticorps monoclonal anti-sclérostine. ; A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody.

المؤلفون: Bolland, Meilyn, Malaise, Olivier, Ribbens, Clio

المصدر: Revue Médicale de Liège, 78 (4), 239 - 244 (2023-04)

العلاقة: urn:issn:0370-629X; urn:issn:2566-1566; https://orbi.uliege.be/handle/2268/312146Test; info:hdl:2268/312146; scopus-id:2-s2.0-85152620812; info:pmid:37067842

الإتاحة: https://orbi.uliege.be/handle/2268/312146Test

View record in BASE

3

Effects of sclerostin antibody on bone healing

المؤلفون: Takashi Sakai, Norihiro Nishida, Kiminori Yukata, Yuji Nagao, Atsushi Mihara, Ryuta Iwanaga, Kenzo Fujii, Toshihiro Seki

المصدر: World Journal of Orthopedics

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a973dd3ec4482bf5201d086aca5ae0Test
https://doi.org/10.5312/wjo.v12.i9.651Test

4

Bone healing of distal radius nonunion treated with bridge plating with bone graft substitutes in combination with systemic romosozumab administration: A case report

المؤلفون: Sadahiko Konishi, Takuya Uemura, Koichi Yano, Hiroaki Nakamura, Yusuke Miyashima, Hiroyuki Yasuda, Kiyohito Takamatsu

المصدر: Joint Diseases and Related Surgery

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97af75fdc07626428d74743e02c9d3f3Test
https://doi.org/10.52312/jdrs.2021.82661Test

5

Denosumab versus romosozumab for postmenopausal osteoporosis treatment

المؤلفون: Takako Suzuki, Jun Takahashi, Makoto Saito, Tomonori Kobayakawa, Yukio Nakamura, Akiko Miyazaki

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Science, Romosozumab, Urology, 030209 endocrinology & metabolism, Article, Bone resorption, Bone remodeling, 03 medical and health sciences, Endocrinology, Medical research, 0302 clinical medicine, Bone Density, medicine, Humans, Molecular Targeted Therapy, Propensity Score, Adverse effect, Osteoporosis, Postmenopausal, Aged, Femoral neck, Aged, 80 and over, Bone mineral, Multidisciplinary, Bone Density Conservation Agents, business.industry, Therapeutic effect, Antibodies, Monoclonal, Middle Aged, Treatment Outcome, Denosumab, medicine.anatomical_structure, Medicine, Female, 030101 anatomy & morphology, business, Biomarkers, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d02a827557d2afbb47a4336faee9eea4Test
https://doaj.org/article/1b85915e4614449ba0b1d9cc85b515ffTest

6

Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study

المؤلفون: K. Okazaki, H. Nishi, K. Wada, Y. Kato, A. Tominaga, Y. Terayama

المصدر: Osteoporosis International

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b85cc9e1410b8496e2f1909dce832ee5Test
https://doi.org/10.1007/s00198-021-05925-3Test

7

The effect of osteoporosis treatment on bone mass

المؤلفون: Appelman-Dijkstra, N.M., Oei, H.L.D.W., Vlug, A.G., Winter, E.M.

المساهمون: Internal Medicine

المصدر: Best Practice and Research: Clinical Endocrinology and Metabolism, 36(2). ELSEVIER SCI LTD
Best Practice & Research Clinical Endocrinology & Metabolism, 36(2):101623. Bailliere Tindall Ltd

مصطلحات موضوعية: bone mass, Bone Density Conservation Agents, Endocrinology, Diabetes and Metabolism, denosumab, fractures, osteoporosis, Fractures, Bone, Endocrinology, SDG 3 - Good Health and Well-being, Bone Density, Humans, Bone Resorption, romosozumab, discontinuation